Image
Marius Wernig

Marius Wernig

Professor, Pathology - Pathology Stem Cell Institute
Professor (By courtesy), Chemical and Systems Biology
Member, Bio-X
Member, Cardiovascular Institute
Member, Institute for Stem Cell Biology and Regenerative Medicine
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute
M.D., Technical University of Munich, Medicine (2000)
Dr. Wernig is a Professor in the Departments of Pathology and Chemical and Systems Biology and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. He graduated with an M.D. Ph.D. from the Technical University of Munich where he trained in developmental genetics in the lab of Rudi Balling. After completing his residency in Neuropathology and General Pathology at the University of Bonn, he then became a postdoctoral fellow in the lab of Dr. Rudolf Jaenisch at the Whitehead Institute for Biomedical Research/ MIT in Cambridge, MA.

He received an NIH Pathway to Independence Award, the Cozzarelli Prize for Outstanding Scientific Excellence from the National Academy of Sciences U.S.A., the Outstanding Investigator Award from the International Society for Stem Cell Research, the New York Stem Cell Foundation Robertson Stem Cell Prize, and more recently was awarded the Ogawa-Yamanaka Stem Cell Prize presented by the Gladstone Institutes and has been named a HHMI Faculty Scholar.

Dr. Wernig’s lab is interested in pluripotent stem cell biology and the molecular determinants of neural cell fate decisions. His laboratory was the first to generate functional neuronal cells reprogrammed directly from skin fibroblasts, which he termed induced neuronal (iN) cells. The lab is now working on identifying the molecular mechanisms underlying induced lineage fate changes, the phenotypic consequences of disease-causing mutations in human neurons and other neural lineages as well as the development of novel therapeutic gene targeting and cell transplantation-based strategies for a variety of monogenetic diseases.